SST0116CL1 in the studies in vitro was shown to inhibit recombinant Hsp90α and to induce the degradation of the oncogenic Her2 tyrosine kinase in BT-474 human breast cancer cells. This evidence concerns the gene HSP90AA1 and breast carcinoma.